Alnylam Pharmaceuticals' Assets Average rose 14.64% to $4.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 billion, marking a year-over-year increase of 14.64%. This contributed to the annual value of $4.0 billion for FY2024, which is 9.40% up from last year.
Latest data reveals that Alnylam Pharmaceuticals reported Assets Average of $4.7 billion as of Q3 2025, which was up 7.26% from $4.4 billion recorded in Q2 2025.
In the past 5 years, Alnylam Pharmaceuticals' Assets Average registered a high of $4.7 billion during Q3 2025, and its lowest value of $3.3 billion during Q1 2021.
In the last 3 years, Alnylam Pharmaceuticals' Assets Average had a median value of $3.9 billion in 2024 and averaged $4.0 billion.
Per our database at Business Quant, Alnylam Pharmaceuticals' Assets Average soared by 42.52% in 2021 and then declined by 1.96% in 2023.
Over the past 5 years, Alnylam Pharmaceuticals' Assets Average (Quarterly) stood at $3.6 billion in 2021, then dropped by 0.48% to $3.5 billion in 2022, then rose by 8.29% to $3.8 billion in 2023, then rose by 10.12% to $4.2 billion in 2024, then grew by 14.64% to $4.7 billion in 2025.
Its Assets Average was $4.7 billion in Q3 2025, compared to $4.4 billion in Q2 2025 and $4.2 billion in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value